News

Learn how integrated platforms, single sign-on tools, and streamlined training approaches can reduce site burden while supporting compliance and study startup.

Discover how reducing redundancy in feasibility processes and leveraging shared databases can improve collaboration and ease site burden.

At the 2025 SCRS Global Site Solutions Summit, site leaders shared insights on when and how to sell a clinical research site, stressing the importance of timing, cultural alignment, personal goals, and clear terms for long-term success.

FDA outlines its limited operations during the funding lapse, focusing on essential public health activities while halting new drug applications.

In a breakout session at the 2025 SCRS Global Site Solutions Summit, industry leaders from SCRS, QCR, and Syneos Health discussed how sites can prioritize patient empowerment, strengthen community outreach, and collaborate with CROs and sponsors to secure resources for engagement initiatives.

Learn how the lack of integration across platforms creates complexity for sites and why holistic solutions are key to reducing data entry and system burden.

At the 2025 SCRS Global Site Solutions Summit, industry experts discussed how sites can balance culture, staffing, and training while expanding across multiple locations.

Explore how stronger collaboration and closed feedback loops can improve communication, change management, and site engagement in clinical trials.

Interviews with biopharma leaders and outsourcing partners reveal emerging trends in clinical trial resourcing models, highlighting a shift away from traditional full-service CRO arrangements toward hybrid strategies that balance in-house expertise, trusted consultants, and selective outsourcing.

Remote monitoring solution for cytokine release syndrome paves the way for more consistent patient care, a deeper understanding of immune responses, ultimately widening patient access to life-saving immunotherapy and reducing recruitment barriers in clinical trials.

Last week’s top stories explored the push for digital-first clinical data systems, why cybersecurity must be central in CRO qualification, and how AI-driven contracting tools are helping sponsors cut delays and accelerate trial timelines.

Tom Cowen, head, healthcare, life sciences, Conga, explains how biotech startups use scalable contract management platforms to efficiently manage clinical trials, support CRO partnerships, and accelerate drug development pipelines.

The FDA has approved Eli Lilly’s Inluriyo (imlunestrant), the first oral estrogen receptor antagonist for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, based on Phase III EMBER-3 results showing a 38% reduction in risk of progression or death versus endocrine therapy.

Tom Cowen, head, healthcare, life sciences, Conga, shares how leading pharmaceutical companies are using Contract Lifecycle Management to streamline global studies, reduce onboarding times, and standardize clinical trial processes.

In this video interview, Ananth Kadambi, VP of real-world evidence and modeling solutions at Certara, highlights how clinical operations teams must enhance patient tracking, engage data monitoring committees earlier, and plan subgroup analyses to meet FDA’s overall survival guidance.

Based on Phase III DESTINY-Breast09 results showing a 44% reduction in risk of progression or death versus standard therapy, AstraZeneca and Daiichi Sankyo’s Enhertu-pertuzumab combination could mark the first major advance in this treatment setting in over a decade.

Pharma R&D faces rising trial complexity, high costs, and patient and investigator shortages, driving the need for adaptive models and data-driven strategies to speed therapies to market.

In this video interview, Ananth Kadambi, VP of real-world evidence and modeling solutions at Certara, explains how integrating real-world evidence and predictive modeling early in development can streamline OS-focused trials while meeting regulatory and payer expectations.

Tom Cowen, head, healthcare, life sciences, Conga, outlines how AI-driven contract management helps pharmaceutical companies simplify global clinical studies, reduce risks, and accelerate trial timelines.

As clinical research becomes increasingly digital, integrating rigorous cybersecurity assessments into CRO selection and qualification is essential to safeguard sensitive data and ensure trial integrity.

Modernizing Clinical Trials: A Site-Centered Roadmap for the Future Simplifying startup, empowering sites through networks, and adopting evidence-based site selection frameworks can address enrollment bottlenecks, reduce dropout, and strengthen trial efficiency across the research ecosystem.

Tom Cowen, head, healthcare, life sciences, Conga, explains why investigator onboarding creates significant delays in clinical trials and how smarter contract management can help sponsors accelerate study start-up.

In this video interview, Ananth Kadambi, VP of real-world evidence and modeling solutions at Certara, discusses how model-informed drug development can help sponsors predict efficacy and safety outcomes to align shorter trials with FDA expectations for overall survival.

Michel van Harten, MD, CEO, myTomorrows; and Kyle McAllister, co-founder, CEO, Trially, discuss how artificial intelligence can reduce barriers for underrepresented patients and streamline prescreening and outreach to support clinical research participation.

In this video interview, Ananth Kadambi, VP of real-world evidence and modeling solutions at Certara, explains how emphasizing overall survival ties trial success to both efficacy and safety while also shaping payer and access considerations post-approval.

Paul Shawah, EVP, strategy, Veeva Systems and Richard Staub, president, R&D solutions, IQVIA, discuss how their partnership is evolving to support decentralized and hybrid clinical trials by combining advanced technology with operational expertise to improve patient engagement, streamline processes, and accelerate study timelines.

In Stage 1 of the Phase II LANTIC study, Ipsen’s novel recombinant molecule IPN10200 met its primary endpoint with significant improvement at week 4 versus placebo and showed longer duration of effect versus Dysport, with most patients maintaining meaningful response at week 24.

This episode of the Applied Clinical Trials Brief highlights a new global collaboration between two industry leaders, explores how site networks can address enrollment and retention challenges, and examines how generative AI is transforming clinical study reporting.